Publication | Closed Access

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Metastatic Breast CancerOncologyBreast OncologyMedicineAromatasePharmacotherapyBreast CancerCancer TreatmentPharmacologyRadiation OncologyEndocrine-related Cancer